BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40

Benzinga · 2d ago
BTIG analyst Kambiz Yazdi maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and raises the price target from $34 to $40.